-Search query
-Search result
Showing 1 - 50 of 289 items for (author: kao & c)
EMDB-35029:
SARS-CoV2 spike protein with ACE2, no ACE2 binding.
Method: single particle / : Kishikawa J, Hirose M, Kato T, Okamoto T
EMDB-35030:
SARS-CoV2 spike protein with ACE2. 1 ACE2 bound form.
Method: single particle / : Kishikawa J, Hirose M, Kato T, Okamoto T
EMDB-35031:
SARS-CoV2 spike protein with ACE2. 2 ACE2 bound form.
Method: single particle / : Kishikawa J, Hirose M, Kato T, Okamoto T
EMDB-35032:
SARS-CoV2 spike protein with ACE2. 3 ACE2 bound form.
Method: single particle / : Kishikawa J, Hirose M, Kato T, Okamoto T
EMDB-35036:
SARS-CoV2 spike protein with ACE2 decoy.no ACE2 decoy binding
Method: single particle / : Kishikawa J, Hirose M, Kato T, Okamoto T
EMDB-35037:
SARS-CoV2 spike protein with ACE2 decoy. 1 ACE2 decoy bound form.
Method: single particle / : Kishikawa J, Hirose M, Kato T, Okamoto T
EMDB-35038:
SARS-CoV2 spike protein with ACE2 decoy. 1 ACE2 decoy bound and 2 RBD up form.
Method: single particle / : Kishikawa J, Hirose M, Kato T, Okamoto T
EMDB-35039:
SARS-CoV2 spike protein with ACE2 decoy. 2 ACE2 decoy bound form.
Method: single particle / : Kishikawa J, Hirose M, Kato T, Okamoto T
EMDB-35040:
SARS-CoV2 spike protein with ACE2 decoy. 3 ACE2 decoy bound form.
Method: single particle / : Kishikawa J, Hirose M, Kato T, Okamoto T
EMDB-36345:
RBD of SARS-CoV2 spike protein with ACE2 decoy
Method: single particle / : Kishikawa J, Hirose M, Kato T, Okamoto T
PDB-8jje:
RBD of SARS-CoV2 spike protein with ACE2 decoy
Method: single particle / : Kishikawa J, Hirose M, Kato T, Okamoto T
EMDB-16532:
Structure of Tau filaments Type I from Subacute Sclerosing Panencephalitis
Method: helical / : Qi C, Hasegawa M, Takao M, Sakai M, Akagi M, Iwasaki Y, Yoshida M, Scheres SHW, Goedert M
EMDB-16535:
Structure of Tau filaments Type II from Subacute Sclerosing Panencephalitis
Method: helical / : Qi C, Hasegawa M, Takao M, Sakai M, Akagi M, Iwasaki Y, Yoshida M, Scheres SHW, Goedert M
PDB-8caq:
Structure of Tau filaments Type I from Subacute Sclerosing Panencephalitis
Method: helical / : Qi C, Hasegawa M, Takao M, Sakai M, Akagi M, Iwasaki Y, Yoshida M, Scheres SHW, Goedert M
PDB-8cax:
Structure of Tau filaments Type II from Subacute Sclerosing Panencephalitis
Method: helical / : Qi C, Hasegawa M, Takao M, Sakai M, Akagi M, Iwasaki Y, Yoshida M, Scheres SHW, Goedert M
EMDB-34741:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-11
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-34742:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-11 focused on RBD and NIV-11 interface
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
PDB-8hgl:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-11
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
PDB-8hgm:
Structure of SARS-CoV-2 spike RBD in complex with neutralizing antibody NIV-11
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33820:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-8 focused on RBD and NIV-8 interface
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33821:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-8 (state 1)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33822:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-8 (state 2)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33823:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-10 focused on RBD and NIV-10 interface
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33824:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-10 (state 1)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33825:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-10 (state 2)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33826:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-10 (state 3)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33827:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-13 focused on RBD and NIV-13 interface
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33828:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-13 (state 1)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33829:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-13 (state 2)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33830:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-13 (state 3)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
PDB-7yh6:
Structure of SARS-CoV-2 spike RBD in complex with neutralizing antibody NIV-8
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
PDB-7yh7:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-8 (state 2)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-35622:
SARS-CoV-2 XBB.1 spike glycoprotein (closed-1 state)
Method: single particle / : Anraku Y, Kita S, Yajima H, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
EMDB-35623:
SARS-CoV-2 XBB.1 spike glycoprotein (closed-2 state)
Method: single particle / : Anraku Y, Kita S, Yajima H, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
EMDB-35624:
SARS-CoV-2 XBB.1 spike glycoprotein in complex with ACE2 (1-up state)
Method: single particle / : Anraku Y, Kita S, Yajima H, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
EMDB-35626:
SARS-CoV-2 XBB.1 spike glycoprotein in complex with ACE2 focused on RBD-ACE2 interface
Method: single particle / : Anraku Y, Kita S, Yajima H, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
PDB-8ios:
Structure of the SARS-CoV-2 XBB.1 spike glycoprotein (closed-1 state)
Method: single particle / : Anraku Y, Kita S, Yajima H, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
PDB-8iot:
Structure of the SARS-CoV-2 XBB.1 spike glycoprotein (closed-2 state)
Method: single particle / : Anraku Y, Kita S, Yajima H, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
PDB-8iou:
Structure of SARS-CoV-2 XBB.1 spike glycoprotein in complex with ACE2 (1-up state)
Method: single particle / : Anraku Y, Kita S, Yajima H, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
PDB-8iov:
Structure of SARS-CoV-2 XBB.1 spike RBD in complex with ACE2
Method: single particle / : Anraku Y, Kita S, Yajima H, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
EMDB-35625:
SARS-CoV-2 XBB.1 spike glycoprotein in complex with ACE2 (2-up state)
Method: single particle / : Anraku Y, Kita S, Yajima H, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
EMDB-29673:
Bulky DNA lesion recognition complex 3
Method: single particle / : Kim J, Yang W
EMDB-29674:
Initial DNA-lesion (Cy5) binding by XPC and TFIIH focused
Method: single particle / : Kim J, Yang W
EMDB-27996:
Initial DNA-lesion (Cy5) binding by XPC and TFIIH
Method: single particle / : Kim J, Yang W
EMDB-27997:
XPA repositioning Core7 of TFIIH relative to XPC-DNA lesion (Cy5)
Method: single particle / : Kim J, Yang W
EMDB-27998:
XPC release from Core7-XPA-DNA (Cy5)
Method: single particle / : Kim J, Yang W
EMDB-27999:
Initial DNA-lesion (AP) binding by XPC and TFIIH complex 1
Method: single particle / : Kim J, Yang W
EMDB-28000:
Initial DNA-lesion (AP) binding by XPC and TFIIH complex2
Method: single particle / : Kim J, Yang W
EMDB-28001:
XPA repositioning Core7 of TFIIH relative to XPC-DNA lesion (AP)
Method: single particle / : Kim J, Yang W
EMDB-28002:
XPC release from Core7-XPA-DNA (AP)
Method: single particle / : Kim J, Yang W
Pages: